

INVITATION

THURSDAY FEBRUARY
07

2ND FRENCH "ADVANCING IMMUNOMODULATION" MEETING NOVOTEL LES HALLES, PARIS

This information is intended only for healthcare professionals in Europe.

PRELIMINARY AGENDA

10:00-10:30am **Registration & coffee**

10:30-10:45am **Welcome & Introduction**

Chairman: **Pr Didier Blaise**, Institut Paoli Calmette, Marseille, France

Graft vs Host Disease (GvHD) Physiopathology and Importance of Immunomodulation

10:45-11:30am **GvHD physiopathology: recent data, the fine line between GvHD and GvL, promoting tissue repair...**

Presentation (10:45-11:15am) Q&A (11:15-11:30am)

Dr James Griffin, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

11:30-12:15pm **The importance and advantages of treating GvHD by immunomodulation (opposed to immunosuppression)**

Presentation (11:30-12:00am) Q&A (12:00-12:15pm)

Prof. Bipin Savani, Vanderbilt University Medical Center, Nashville, USA

12:15-12:30pm **Wrap-up / Conclusions of morning presentations**

12:30-1:30pm **Lunch**

Graft vs Host Disease (GvHD) management: therapeutic options leading to immunodulation

1:30-2:15pm **Immunomodulation induced by apoptosis of mesenchymal stromal cells: applied to GvHD treatment**

Presentation (1:30-2:00pm) Q&A (2:00-2:15pm)

Pr Francesco Dazzi, Imperial College Faculty of Medicine, London, UK

2:15-3:00pm **Immunomodulation induced by ECP: applied to acute GvHD treatment**

Presentation (2:15-2:45pm) Q&A (2:45-3:00pm)

Dr Angela Granata, Institut Paoli Calmette, Marseille, France

3:00-3:45pm **Recent trends and near future**

Presentation (3:00-3:30pm) Q&A (3:30-3:45pm)

Dr Florent Malard, Hôpital Saint Antoine, Paris, France

3:45-4:15pm **Wrap-up / Conclusions of afternoon presentations**

Conclusions of the day

Pr Didier Blaise, Institut Paoli Calmette, Marseille, France

4:15pm **Meeting closure, Coffee networking**

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company

[Privacy policy](#) [Legal notice](#)

Learn more about Mallinckrodt Pharmaceuticals by visiting www.mallinckrodt.com

Mallinckrodt, the "M" brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2018 Mallinckrodt.

Item code: EU-1800008. Date of preparation: October 2018.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating "unsubscribe" in the email body. Our Privacy Notice provides additional information.